Related Experiment Videos
Protein kinases in the action of vasopressin
1University of Colorado School of Medicine, Denver, USA.
Kidney International. Supplement
|November 5, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2010
p38 MAP kinase modulates liver cell volume through inhibition of membrane Na+ permeability.
The Journal of clinical investigation·2001
The expression of the gamma subunit of Na-K-ATPase is regulated by osmolality via C-terminal Jun kinase and phosphatidylinositol 3-kinase-dependent mechanisms.
Proceedings of the National Academy of Sciences of the United States of America·2001
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
The New England journal of medicine·2001
Long-term adaptation of renal cells to hypertonicity: role of MAP kinases and Na-K-ATPase.
American journal of physiology. Renal physiology·2001
Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent.
Oncology (Williston Park, N.Y.)·2000
Effect of kidney disease on glucose handling (including genetic defects).
Kidney international. Supplement·2011
Need for better diabetes treatment for improved renal outcome.
Kidney international. Supplement·2011
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
Kidney international. Supplement·2011
SGLT2 inhibitors: molecular design and potential differences in effect.
Kidney international. Supplement·2011
Glucose handling by the kidney.
Kidney international. Supplement·2011
Bone: from a reservoir of minerals to a regulator of energy metabolism.
Kidney international. Supplement·2011
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
Handbook of experimental pharmacology·2026
Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?
The Journal of clinical endocrinology and metabolism·2026
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Immunity, inflammation and disease·2026